The real‑world analysis, presented at the 2026 American Psychiatric Association Annual Meeting in San Francisco, highlights that TD remains both underrecognized and delayed in diagnosis—even when patients report significant functional and psychological impact. Among adults aged 18 to 29 with mood disorders and observable TD symptoms, only 23% had received a formal diagnosis. This contrasts sharply with the reported burden, as 85% in this group experienced moderate to severe impairment related to the condition.

Broad Impact Across Age Groups

Tardive dyskinesia, characterized by involuntary movements often associated with long‑term use of certain psychiatric medications, was shown to have a meaningful impact across the adult lifespan. Data from the registry indicate that most participants, regardless of age, reported moderate to severe overall effects on daily living.

While the youngest cohort experienced one of the lowest diagnostic rates, the burden of disease was not confined to this group. Adults aged 50–59 also showed similarly high levels of impact, with 87% reporting moderate to severe effects. Meanwhile, older adults appeared to experience the most pronounced psychological burden, suggesting that emotional and mental health consequences may intensify with age.

Delayed Recognition and Diagnosis

Beyond low diagnostic rates, the analysis revealed that TD diagnosis is often significantly delayed. On average, more than three and a half years elapsed between the initial recognition of involuntary movements and formal diagnosis. This lag may contribute to prolonged patient distress and missed opportunities for intervention.

The study focused on a subset of 211 adults with TD and coexisting mood disorders—primarily bipolar disorder and depression—who were not receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy at the time of enrollment. This population reflects a real‑world clinical setting in which TD may go untreated or unrecognized despite evident symptoms.

Study Design and Scope

The IMPACT‑TD Registry is a large, prospective, three‑year Phase 4 observational study designed to better understand how TD evolves and affects patients over time. It includes a diverse population of more than 600 adults with varying demographic and clinical characteristics. Researchers use tools such as the Abnormal Involuntary Movement Scale (AIMS) to assess severity and the clinician‑reported IMPACT‑TD scale to measure multidimensional effects, including functional, social, and emotional domains.

Clinical Implications

The findings point to a critical need for improved screening and awareness of TD, especially in younger populations with mood disorders who may be overlooked. Clinicians may underestimate the presence or significance of symptoms in this group, contributing to underdiagnosis.

Experts involved in the study emphasize that TD affects more than visible motor symptoms. It can interfere with independence, social engagement, and overall quality of life. Recognizing these broader consequences is essential to providing appropriate care and support.

Addressing the Gap

The data reinforce the importance of earlier identification and more consistent monitoring of patients at risk for TD. Improved diagnostic practices could help reduce the time to treatment and mitigate long‑term impact.

Ongoing research efforts, including the IMPACT‑TD Registry, aim to deepen understanding of how TD manifests in different populations and to guide strategies that enhance patient outcomes. Closing the diagnostic gap remains a key priority, particularly for underserved or underrecognized groups such as younger adults living with mood disorders.